Testing the Impact of Pre-visit Priming for Medications

We will use EHR data to identify eligible patients at BWH primary care clinics. Patients will be eligible if they have an upcoming primary care provider (PCP) appointment at an included BWH clinic, are ≥65 years, and are eligible for a medication target; exclusion criteria will include relevant EHR-documented allergies. After sharing patients with PCPs for potential opt-out, patients will be randomized 1:1 in REDCap® to intervention or usual care (no prompt). The intervention will include a pre-visit patient-facing prompt with information about the evidence-based medication target. If patients are eligible for multiple targets, one will be randomly selected. The primary clinical outcome will be measured on the day of the PCP visit using EHR data, depending on target: a) discontinuation or tapering order, or b) prescribing. Secondary outcomes will include a) these same measures in a 60-day follow-up period after the visit to capture any follow-up actions. We will use an intention-to-treat approach including patients regardless of whether the visit occurred. We plan to conduct the trial until 1700 patients are reached. We will also conduct exploratory mediation analyses of mechanisms through brief patient surveys with behavioral scales and PCP survey.

NCT Number	NCT07281131
Lead Sponsor	Brigham and Women's Hospital Collaborators: National Institute on Aging (NIA), University of Southern California
Conditions	Deprescribing, Statin Prescribing
Enrollment	1,700 participants
Start Date	2026-06-10
Primary Completion	2026-09-15 (estimated)
Study Completion	2026-11-14 (estimated)
Updated on ClinicalTrials.gov	2026-06-15